The FDA released draft guidance on decentralized clinical trials (DCTs) in May 2023.
Our clinical science and trial optimization experts reviewed the guidance and provide a summary of its key themes as well as offer their perspectives in this white paper.
You’ll learn about applications for technology in DCTs, considerations for investigator oversight, and preserving data precision and integrity.
Read the paper to find out how this guidance might inform your next study.
